Abiomed 4Q sales up 17 percent, top Wall St. view
Abiomed forecasts 4Q sales rose 17 percent, beating Wall Street expectations
DANVERS, Mass. (AP) -- Abiomed Inc. forecast that revenue in its fiscal fourth quarter rose 17 percent to $43.7 million, better than analysts had expected, because more hospitals bought its heart devices.
Analysts polled by FactSet had expected revenue of $41.5 million in the January-March period.
The Danvers, Mass., company will report full fourth-quarter results on May 2.
According to preliminary estimates, revenue from Impella heart pumps rose 22 percent to $39.3 million. During the quarter, 30 U.S. hospitals purchased its Impella 2.5 device, bringing its total U.S. customers to 748. And 55 hospitals purchased its new Impella CP device, bringing users to 101.
Abiomed shares jumped $1.28, or 7.8 percent, to $17.61 in morning trading Wednesday.
